Cartesian Therapeutics, Inc. is a US-based pharmaceutical company with a medium risk rating score of 28.9. Specializing in immune tolerance technology, Cartesian Therapeutics uses its ImmTOR platform to enhance antigen-specific immunity and regulate immune responses. By introducing mRNA molecules into cells, the company aims to improve cell function without altering genetic material. Experience innovative biopharmaceutical solutions at Cartesian Therapeutics, Inc.